Rheumatoid Arthritis Drugs Market Size, Share, Growth Analysis, By Drug Class(Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs), By Route of Administration(Oral, Parenteral), By Sales Channel(Prescription-based Drugs, Over-the-counter Drugs), By Molecule(Pharmaceuticals and Biopharmaceuticals), By Region - Industry Forecast 2024-2031


Report ID: SQSG35I2003 | Region: Global | Published Date: April, 2024
Pages: 242 |Tables: 115 |Figures: 69

Rheumatoid Arthritis Drugs Market Insights

Rheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2019 and is poised to grow from USD 60.02 billion in 2023 to USD 70 billion by 2031, growing at a CAGR of 1.72% in the forecast period (2024-2031).

Rheumatoid arthritis affects people of all ages, although the geriatric population is highly vulnerable to the diseases. The symptoms majorly include joint pain, stiffness, tenderness, and swelling. As per the statistics published by WHO, rheumatoid arthritis affected around 400 out of 100,000 people between 1980 and 2019. Despite high prevalence, it does not have 100% cure.

The major factors driving growth in the Global market are an increase in the prevalence of rheumatoid arthritis, an increase in demand for rheumatoid arthritis drugs, the expiration of patents and the entry of biosimilar drugs, an increase in the geriatric population, an increase in the adoption of conventional DMARDs, and government initiatives to spread awareness of rheumatoid arthritis symptoms. Furthermore, advancements in sophisticated biologics, an increase in healthcare expenditure, an increase in purchasing power, and global access to quality pharmaceuticals for poor and middle-class families are some of the factors driving Global Rheumatoid Arthritis Drugs Market expansion.

US Rheumatoid Arthritis Drugs Market is poised to grow at a sustainable CAGR for the next forecast year.

Market Snapshot - 2024-2031

Global Market Size

USD 59.031 billion

Largest Segment

Prescription Drugs

Fastest Growth

Prescription Drugs

Growth Rate

1.72% CAGR

Global Rheumatoid Arthritis Drugs Market, 2021-2028 ($ Bn)
Country Share for North America Region- 2021 (%)

To get more reports on the above market click here to Buy The Report

Rheumatoid Arthritis Drugs Market Segmental Analysis

Global Rheumatoid Arthritis Drugs market is segmented by Drug Class into Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, and Uric Acid Drugs. By molecule, the market is segmented into Pharmaceuticals and Biopharmaceuticals. By Route of Administration, the market is segmented into Oral and Parenteral. By Sales Channel the market is segmented into Prescription Drugs and OTC drugs. Based on the region it is categorized into North America, Europe, Asia-Pacific, South America, and MEA.

Rheumatoid Arthritis Drugs Market Analysis by Drug Class

Currently, disease-modifying anti-rheumatic medicines (DMARDs) are the leading revenue contributors and are expected to expand significantly in the Global Rheumatoid Arthritis Drugs Market during the forecast period. The increase in DMARD awareness, surge in rheumatoid arthritis prevalence, rise in obese & overweight population globally, and increase in usage of DMARDs as a first-line treatment for rheumatoid arthritis are the important reasons driving global market growth.

Global Rheumatoid Arthritis Drugs Market Share By Sales Channel , 2021(%)

To get detailed analysis on other segments, Request For Free Sample Report

Rheumatoid Arthritis Drugs Market Regional Insights

North America holds majority share and is likely to maintain its dominant position in the Global Rheumatoid Arthritis Drugs market over the forecast period. Due to the presence of a large population base susceptible to rheumatoid arthritis, increased public awareness about the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in rheumatoid arthritis drug adoption, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, the rise in geriatric population and increased demand for DMARDs contribute to global market growth. Furthermore, the increased focus of top manufacturers on increasing their geographical presence in rising Asia-Pacific countries in order to acquire a large portion of the Global Rheumatoid Arthritis Drugs market is likely to boost growth.

Global Rheumatoid Arthritis Drugs Market Size By Geography, 2021 - 2028
  • Largest
  • Fastest

To know more about the market opportunities by region and country, click here to
Buy The Complete Report

Rheumatoid Arthritis Drugs Market Dynamics

Rheumatoid Arthritis Drugs Market Driver

Increasing Efficacy of Medications in the Treatment of Rheumatoid Arthritis, Combined with Favorable Reimbursement Policies

Global rheumatoid arthritis drugs market is projected to grow at a CAGR of 2.75% from 2022 to 2028, owing to increasing efficacy of medications in the treatment of RA and favorable reimbursement policies. The market for biologics is expected to grow at a higher rate, owing to the advent of novel therapies and increasing awareness about the disease. Currently, there are two types of rheumatoid arthritis drugs available in the market, namely monoclonal antibodies (MoA) and non-biologic agents. MoA drugs are more expensive than non-biologic agents, but have a higher efficacy rate. Non-biologic agents are cheaper than MoA drugs, but their efficacy rate is lower. The growing geriatric population is expected to drive the growth of the rheumatoid arthritis drugs market during the forecast period. Wherein, the biologics category is expected to hold the highest market share.

Rheumatoid Arthritis Drugs Market Restraint

High Treatment Cost

  • Rheumatoid arthritis drugs are expensive and patients often end up paying up to USD 30,000 on the medication each year. It has also been found that most of the patients have to cover the expenses out of their pockets and it can be reimbursed by insurance providers, depending on the coverage amount. Despite the insurance coverage, patient has to pay up to 30% of the cost on their own.

Request Free Customization of this report to help us to meet your business objectives.

Rheumatoid Arthritis Drugs Market Competitive Landscape

Global rheumatoid arthritis drugs market has become moderately competitive. This is partly because there are a number of new drugs available that can help to treat the condition. However, it is also due to the fact that existing drugs are being marketed in a more aggressive way. This means that companies are investing more in marketing their products, which in turn leads to higher sales volumes. The major players in this market are focusing on developing new and innovative products that can address the needs of patients. This is expected to drive the growth of the rheumatoid arthritis drugs market over the forecast period.

Top Player’s in Global Rheumatoid Arthritis Drugs Market

  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Co.
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis International AG
  • Sanofi S.A.
    UCB S.A.
    Biogen Idec Inc.
    Gilead Sciences, Inc.
    Astellas Pharma Inc.
    Daiichi Sankyo Company Limited
    Eisai Co., Ltd.
    Ipsen S.A.
    Kyowa Kirin Co., Ltd.

Rheumatoid Arthritis Drugs Market Recent Developments

  • In June 2022, Cipla and DNDi launched child-friendly 4-in-1 antiretroviral treatment for young children living with HIV in South Africa. The South African Health Products Regulatory Authority (SAHPRA) has approved a sweet-tasting, heat-stable '4-in-1' fixed-dose combination of four antiretroviral (ARV) medications made up of abacavir, lamivudine, lopinavir, and ritonavir for infants and young children with HIV. Cipla Limited and the not-for-profit Drugs for Neglected Diseases initiative (DNDi) designed this combination medicine.
  • In June 2022, Pfizer Inc., one of the key players in the global rheumatoid drug market, completed the acquisition of ReViral, a privately held clinical-stage biopharmaceutical business focused on discovering, developing, and commercializing new antiviral treatments for respiratory syncytial virus (RSV).
  • In June 2022, Sanofi announced the start of its first Digital Accelerator in order to further its goal of being a top digital healthcare organization. Sanofi's objective to transform the practice of medicine via the use of digital, data, and artificial intelligence would be supported by the Accelerator's products and solutions (AI).
  • In June 2022, Amgen Announced that the U.S Food and Drug Administration has approved RIABNI (rituximab-arrx), a biosimilar of Rituxan®, in combination with methotrexate for individuals with moderate to severely active rheumatoid arthritis (RA) who have had an insufficient response to one or more tumor necrosis factor (TNF) antagonist treatments. Adult patients with Non-Lymphoma Hodgkin's (NHL), Chronic Lymphocytic Leukemia (CLL), Granulomatosis with Polyangiitis (GPA) (also known as Wegener's Granulomatosis) and Microscopic Polyangiitis (MPA) are already treated with RIABNI. ""The approval of RIABNI is an important advancement for adults living with moderate to severe rheumatoid arthritis, a chronic inflammatory joint disease, who now have access to a proven and affordable treatment option,"" said Murdo Gordon, executive vice president of Global Commercial Operations at Amgen.

Rheumatoid Arthritis Drugs Key Market Trends

  • Increasing prevalence of rheumatoid arthritis among elderly population. In addition to this, a shift from symptom management to slowing the progression of the disease is driving the growth of the rheumatoid arthritis drugs market.
  • Unavailability of 100% cure is driving demand for drugs that are useful in managing and slowing down the disease progression.
  • Aggressive marketing of drugs
  • Rising launch of novel therapies such as monoclonal antibodies for rheumatoid arthritis, increasing investments by most of the leading players in R&D activities for the development of novel therapies and biosimilars are projected to drive the growth of global rheumatoid arthritis drugs market

Rheumatoid Arthritis Drugs Market SkyQuest Analysis

SkyQuest’s ABIRAW (Advanced Business Intelligence, Research & Analysis Wing) is our business information wireless team that collects, collates, co-relates and analyses the data collected by means of primary exploratory research backed by the robust secondary desk research.

Global Rheumatoid Arthritis Drugs Market research report also captures the market roadmap with market sizes, revenue forecasts, value chain, market & Drug Class trends, price trends and regulations, competitive landscape, leading players, and their key developments, strategy, and profile. According to our analysis North America is likely to maintain its dominant position in the rheumatoid arthritis market over the forecast period.

Report Metric Details
Market size value in 2023 USD 59.031 billion
Market size value in 2031 USD 70 billion
Growth Rate 1.72%
Forecast period 2024-2031
Forecast Unit (Value) USD Billion
Segments covered
  • Drug Class
    • Disease-modifying Anti-rheumatic Drugs, Nonsteroidal Anti-inflammatory Drugs, Corticosteroids, Uric Acid Drugs, Others
  • Route of Administration
    • Oral, Parenteral
  • Sales Channel
    • Prescription-based Drugs, Over-the-counter Drugs
  • Molecule
    • Pharmaceuticals and Biopharmaceuticals
Regions covered North America (US, Canada), Europe (Germany, France, United Kingdom, Italy, Spain, Rest of Europe), Asia Pacific (China, India, Japan, Rest of Asia-Pacific), Latin America (Brazil, Rest of Latin America), Middle East & Africa (South Africa, GCC Countries, Rest of MEA)
Companies covered
  • Pfizer Inc.
  • Johnson & Johnson Services, Inc.
  • AbbVie Inc.
  • Amgen Inc.
  • Bristol Myers Squibb Co.
  • Celgene Corporation
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline plc
  • Merck & Co., Inc.
  • Novartis International AG
  • Sanofi S.A.
    UCB S.A.
    Biogen Idec Inc.
    Gilead Sciences, Inc.
    Astellas Pharma Inc.
    Daiichi Sankyo Company Limited
    Eisai Co., Ltd.
    Ipsen S.A.
    Kyowa Kirin Co., Ltd.
Customization scope

Free report customization with purchase. Customization includes:-

  • Segments by type, application, etc
  • Company profile
  • Market dynamics & outlook
  • Region

Historical Year 2019

To get a free trial access to our platform which is a one stop solution for all your data requirements for quicker decision making. This platform allows you to compare markets, competitors who are prominent in the market, and mega trends that are influencing the dynamics in the market. Also, get access to detailed SkyQuest exclusive matrix.

Buy The Complete Report to read the analyzed strategies adopted by the top vendors either to retain or gain market share

Table Of Content

Executive Summary

Market overview

  • Exhibit: Executive Summary – Chart on Market Overview
  • Exhibit: Executive Summary – Data Table on Market Overview
  • Exhibit: Executive Summary – Chart on Rheumatoid Arthritis Drugs Market Characteristics
  • Exhibit: Executive Summary – Chart on Market by Geography
  • Exhibit: Executive Summary – Chart on Market Segmentation
  • Exhibit: Executive Summary – Chart on Incremental Growth
  • Exhibit: Executive Summary – Data Table on Incremental Growth
  • Exhibit: Executive Summary – Chart on Vendor Market Positioning

Parent Market Analysis

Market overview

Market size

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • SWOT Analysis

KEY MARKET INSIGHTS

  • Technology Analysis
    • (Exhibit: Data Table: Name of technology and details)
  • Pricing Analysis
    • (Exhibit: Data Table: Name of technology and pricing details)
  • Supply Chain Analysis
    • (Exhibit: Detailed Supply Chain Presentation)
  • Value Chain Analysis
    • (Exhibit: Detailed Value Chain Presentation)
  • Ecosystem Of the Market
    • Exhibit: Parent Market Ecosystem Market Analysis
    • Exhibit: Market Characteristics of Parent Market
  • IP Analysis
    • (Exhibit: Data Table: Name of product/technology, patents filed, inventor/company name, acquiring firm)
  • Trade Analysis
    • (Exhibit: Data Table: Import and Export data details)
  • Startup Analysis
    • (Exhibit: Data Table: Emerging startups details)
  • Raw Material Analysis
    • (Exhibit: Data Table: Mapping of key raw materials)
  • Innovation Matrix
    • (Exhibit: Positioning Matrix: Mapping of new and existing technologies)
  • Pipeline product Analysis
    • (Exhibit: Data Table: Name of companies and pipeline products, regional mapping)
  • Macroeconomic Indicators

COVID IMPACT

  • Introduction
  • Impact On Economy—scenario Assessment
    • Exhibit: Data on GDP - Year-over-year growth 2016-2022 (%)
  • Revised Market Size
    • Exhibit: Data Table on Rheumatoid Arthritis Drugs Market size and forecast 2021-2027 ($ million)
  • Impact Of COVID On Key Segments
    • Exhibit: Data Table on Segment Market size and forecast 2021-2027 ($ million)
  • COVID Strategies By Company
    • Exhibit: Analysis on key strategies adopted by companies

MARKET DYNAMICS & OUTLOOK

  • Market Dynamics
    • Exhibit: Impact analysis of DROC, 2021
      • Drivers
      • Opportunities
      • Restraints
      • Challenges
  • Regulatory Landscape
    • Exhibit: Data Table on regulation from different region
  • SWOT Analysis
  • Porters Analysis
    • Competitive rivalry
      • Exhibit: Competitive rivalry Impact of key factors, 2021
    • Threat of substitute products
      • Exhibit: Threat of Substitute Products Impact of key factors, 2021
    • Bargaining power of buyers
      • Exhibit: buyers bargaining power Impact of key factors, 2021
    • Threat of new entrants
      • Exhibit: Threat of new entrants Impact of key factors, 2021
    • Bargaining power of suppliers
      • Exhibit: Threat of suppliers bargaining power Impact of key factors, 2021
  • Skyquest special insights on future disruptions
    • Political Impact
    • Economic impact
    • Social Impact
    • Technical Impact
    • Environmental Impact
    • Legal Impact

Market Size by Region

  • Chart on Market share by geography 2021-2027 (%)
  • Data Table on Market share by geography 2021-2027(%)
  • North America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • USA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Canada
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Europe
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Germany
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Spain
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • France
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • UK
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Europe
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Asia Pacific
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • China
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • India
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Japan
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Korea
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of Asia Pacific
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Latin America
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • Brazil
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of South America
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
  • Middle East & Africa (MEA)
    • Chart on Market share by country 2021-2027 (%)
    • Data Table on Market share by country 2021-2027(%)
    • GCC Countries
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • South Africa
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)
    • Rest of MEA
      • Exhibit: Chart on Market share 2021-2027 (%)
      • Exhibit: Market size and forecast 2021-2027 ($ million)

KEY COMPANY PROFILES

  • Competitive Landscape
    • Total number of companies covered
      • Exhibit: companies covered in the report, 2021
    • Top companies market positioning
      • Exhibit: company positioning matrix, 2021
    • Top companies market Share
      • Exhibit: Pie chart analysis on company market share, 2021(%)

Methodology

For the Rheumatoid Arthritis Drugs Market, our research methodology involved a mixture of primary and secondary data sources. Key steps involved in the research process are listed below:

1. Information Procurement: This stage involved the procurement of Market data or related information via primary and secondary sources. The various secondary sources used included various company websites, annual reports, trade databases, and paid databases such as Hoover's, Bloomberg Business, Factiva, and Avention. Our team did 45 primary interactions Globally which included several stakeholders such as manufacturers, customers, key opinion leaders, etc. Overall, information procurement was one of the most extensive stages in our research process.

2. Information Analysis: This step involved triangulation of data through bottom-up and top-down approaches to estimate and validate the total size and future estimate of the Rheumatoid Arthritis Drugs Market.

3. Report Formulation: The final step entailed the placement of data points in appropriate Market spaces in an attempt to deduce viable conclusions.

4. Validation & Publishing: Validation is the most important step in the process. Validation & re-validation via an intricately designed process helped us finalize data points to be used for final calculations. The final Market estimates and forecasts were then aligned and sent to our panel of industry experts for validation of data. Once the validation was done the report was sent to our Quality Assurance team to ensure adherence to style guides, consistency & design.

Analyst Support

Customization Options

With the given market data, our dedicated team of analysts can offer you the following customization options are available for the Rheumatoid Arthritis Drugs Market:

Product Analysis: Product matrix, which offers a detailed comparison of the product portfolio of companies.

Regional Analysis: Further analysis of the Rheumatoid Arthritis Drugs Market for additional countries.

Competitive Analysis: Detailed analysis and profiling of additional Market players & comparative analysis of competitive products.

Go to Market Strategy: Find the high-growth channels to invest your marketing efforts and increase your customer base.

Innovation Mapping: Identify racial solutions and innovation, connected to deep ecosystems of innovators, start-ups, academics, and strategic partners.

Category Intelligence: Customized intelligence that is relevant to their supply Markets will enable them to make smarter sourcing decisions and improve their category management.

Public Company Transcript Analysis: To improve the investment performance by generating new alpha and making better-informed decisions.

Social Media Listening: To analyze the conversations and trends happening not just around your brand, but around your industry as a whole, and use those insights to make better Marketing decisions.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Rheumatoid Arthritis Drugs Market size was valued at USD 59.031 billion in 2019 and is poised to grow from USD 60.02 billion in 2023 to USD 70 billion by 2031, growing at a CAGR of 1.72% in the forecast period (2024-2031).

rheumatoid arthritis drugs market has become moderately competitive. This is partly because there are a number of new drugs available that can help to treat the condition. However, it is also due to the fact that existing drugs are being marketed in a more aggressive way. This means that companies are investing more in marketing their products, which in turn leads to higher sales volumes. The major players in this market are focusing on developing new and innovative products that can address the needs of patients. This is expected to drive the growth of the rheumatoid arthritis drugs market over the forecast period. 'Pfizer Inc.', 'Johnson & Johnson Services, Inc.', 'AbbVie Inc.', 'Amgen Inc.', 'Bristol Myers Squibb Co.', 'Celgene Corporation', 'Eli Lilly and Company', 'F. Hoffmann-La Roche AG', 'GlaxoSmithKline plc', 'Merck & Co., Inc.', 'Novartis International AG', 'Sanofi S.A.UCB S.A.Biogen Idec Inc.Gilead Sciences, Inc.Astellas Pharma Inc.Daiichi Sankyo Company LimitedEisai Co., Ltd.Ipsen S.A.Kyowa Kirin Co., Ltd.'

Rheumatoid arthritis drugs are expensive and patients often end up paying up to USD 30,000 on the medication each year. It has also been found that most of the patients have to cover the expenses out of their pockets and it can be reimbursed by insurance providers, depending on the coverage amount. Despite the insurance coverage, patient has to pay up to 30% of the cost on their own.

Increasing prevalence of rheumatoid arthritis among elderly population. In addition to this, a shift from symptom management to slowing the progression of the disease is driving the growth of the rheumatoid arthritis drugs market.

North America holds majority share and is likely to maintain its dominant position in the Rheumatoid Arthritis Drugs market over the forecast period. Due to the presence of a large population base susceptible to rheumatoid arthritis, increased public awareness about the use and benefits of these drugs, development of the R&D sector, rise in healthcare reforms, and increase in rheumatoid arthritis drug adoption, Asia-Pacific presents lucrative opportunities for key players operating in the market. Furthermore, the rise in geriatric population and increased demand for DMARDs contribute to market growth. Furthermore, the increased focus of top manufacturers on increasing their geographical presence in rising Asia-Pacific countries in order to acquire a large portion of the Rheumatoid Arthritis Drugs market is likely to boost growth.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Report ID: SQSG35I2003

$5,300
BUY NOW GET FREE SAMPLE